{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:54:23Z","timestamp":1781654063197,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004286","name":"Santen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004286","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Senju"},{"DOI":"10.13039\/100015993","name":"Kowa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015993","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010383","name":"Topcon","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010383","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004419","name":"Wakamoto Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004419","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nidek"},{"name":"Rohto"},{"DOI":"10.13039\/100007816","name":"Alcon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007816","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hoya"},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nitto Medic"},{"DOI":"10.13039\/100010793","name":"Pfizer Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AMO Japan"},{"name":"Glaukos"},{"DOI":"10.13039\/100008680","name":"Sucampo Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008680","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019081","name":"Aerie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019081","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s12325-021-02035-8","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T13:11:09Z","timestamp":1643029869000},"page":"1359-1374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan"],"prefix":"10.1007","volume":"39","author":[{"given":"Toru","family":"Nakazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Kuwayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"2035_CR1","unstructured":"World Health Organization. Visual Impairment and Blindness: Fact Sheet No 282. 2014. Accessed 27 Sep 2021."},{"key":"2035_CR2","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081\u201390.","journal-title":"Ophthalmology"},{"key":"2035_CR3","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1001\/archopht.1994.01090180121046","volume":"112","author":"MC Leske","year":"1994","unstructured":"Leske MC, Connell AM, Schachat AP, Hyman L. The Barbados Eye Study: prevalence of open-angle glaucoma. Arch Ophthalmol. 1994;112:821\u20139.","journal-title":"Arch Ophthalmol"},{"key":"2035_CR4","first-page":"1641","volume":"111","author":"A Iwase","year":"2004","unstructured":"Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111:1641\u20138.","journal-title":"Ophthalmology"},{"key":"2035_CR5","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.ophtha.2015.11.004","volume":"123","author":"KE Kim","year":"2016","unstructured":"Kim KE, Kim MJ, Park KH, et al. Of the Korean ES, Society O. Prevalence, awareness, and risk factors of primary open-angle glaucoma: Korea National Health and Nutrition Examination survey 2008\u20132011. Ophthalmology. 2016;123:532\u201341.","journal-title":"Ophthalmology"},{"key":"2035_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0002-9394(98)00223-2","volume":"126","author":"Collaborative Normal-Tension Glaucoma Study Group","year":"1998","unstructured":"Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487\u201397.","journal-title":"Am J Ophthalmol"},{"key":"2035_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archopht.121.1.48","volume":"121","author":"MC Leske","year":"2003","unstructured":"Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma treatment trial. Arch Ophthalmol. 2003;121:48\u201356.","journal-title":"Arch Ophthalmol"},{"key":"2035_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/APO.0000000000000181","volume":"5","author":"A Cheema","year":"2016","unstructured":"Cheema A, Chang RT, Shrivastava A, Singh K. Update on the medical treatment of primary open-angle glaucoma. Asia Pac J Ophthalmol (Phila). 2016;5:51\u20138.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"2035_CR9","doi-asserted-by":"crossref","unstructured":"European Glaucoma Society. European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition\u2014Chapter 3: treatment principles and options Supported by the EGS Foundation: part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options. Br J Ophthalmol. 2017; Chapter 3;101:130\u201395.","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.003"},{"key":"2035_CR10","doi-asserted-by":"publisher","first-page":"P41","DOI":"10.1016\/j.ophtha.2015.10.053","volume":"123","author":"BE Prum","year":"2016","unstructured":"Prum BE, Rosenberg LF, Gedde SJ, et al. Primary open-angle glaucoma preferred practice pattern\u00ae guidelines. Ophthalmology. 2016;123:P41-111.","journal-title":"Ophthalmology"},{"key":"2035_CR11","unstructured":"The Japan Glaucoma Society Guidelines for Glaucoma (4rd Edition). Nippon Ganka Gakkai Zasshi. 2018;122:3\u201353."},{"key":"2035_CR12","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/S0140-6736(17)31469-1","volume":"390","author":"JB Jonas","year":"2017","unstructured":"Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. Lancet. 2017;390:2183\u201393.","journal-title":"Lancet"},{"key":"2035_CR13","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2147\/OPTH.S63760","volume":"8","author":"JK Schmier","year":"2014","unstructured":"Schmier JK, Hulme-Lowe CK, Covert DW. Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs. Clin Ophthalmol. 2014;8:1097\u2013104.","journal-title":"Clin Ophthalmol"},{"key":"2035_CR14","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.survophthal.2016.03.008","volume":"61","author":"P Tan","year":"2016","unstructured":"Tan P, Malhotra R. Oculoplastic considerations in patients with glaucoma. Surv Ophthalmol. 2016;61:718\u201325.","journal-title":"Surv Ophthalmol"},{"key":"2035_CR15","doi-asserted-by":"publisher","first-page":"6869","DOI":"10.1021\/acs.jmedchem.8b00808","volume":"61","author":"R Iwamura","year":"2018","unstructured":"Iwamura R, Tanaka M, Okanari E, et al. Identification of a selective, non-prostanoid EP2 receptor agonist for the treatment of glaucoma: omidenepag and its prodrug omidenepag isopropyl. J Med Chem. 2018;61:6869\u201391.","journal-title":"J Med Chem"},{"key":"2035_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1167\/iovs.17-22745","volume":"59","author":"T Kirihara","year":"2018","unstructured":"Kirihara T, Taniguchi T, Yamamura K, et al. Pharmacologic characterization of omidenepag isopropyl, a novel selective EP2 receptor agonist, as an ocular hypotensive agent. Invest Ophthalmol Vis Sci. 2018;59:145\u201353.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2035_CR17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1089\/jop.2017.0146","volume":"34","author":"M Fuwa","year":"2018","unstructured":"Fuwa M, Toris CB, Fan S, et al. Effects of a novel selective EP2 receptor agonist, Omidenepag isopropyl, on aqueous humor dynamics in laser-induced ocular hypertensive monkeys. J Ocul Pharmacol Ther. 2018;34:531\u20137.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2035_CR18","unstructured":"Santen Pharmaceutical Co., Ltd, UBE Industries [press release]. Santen and UBE Industries Announce Receipt of Manufacturing and Marketing Approval for Glaucoma and Ocular Hypertension Treatment EYBELIS Ophthalmic Solution 0.002% in Japan. 2018. http:\/\/www.ube-ind.co.jp\/ube\/en\/news\/2018\/20180921_01.html. Accessed 20 May 2019"},{"key":"2035_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ajo.2020.06.003","volume":"220","author":"M Aihara","year":"2020","unstructured":"Aihara M, Lu F, Kawata H, Iwata A, Odani-Kawabata N, Shams NK. Omidenepag isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension: the phase 3 AYAME study. Am J Ophthalmol. 2020;220:53\u201363.","journal-title":"Am J Ophthalmol"},{"key":"2035_CR20","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s10384-020-00748-x","volume":"64","author":"M Aihara","year":"2020","unstructured":"Aihara M, Ropo A, Lu F, et al. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non\u2212\/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study. Jpn J Ophthalmol. 2020;64:398\u2013406.","journal-title":"Jpn J Ophthalmol"},{"key":"2035_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1089\/jop.2020.0071","volume":"37","author":"M Fuwa","year":"2021","unstructured":"Fuwa M, Shimazaki A, Odani-Kawabata N, et al. Additive intraocular pressure-lowering effects of a novel selective EP2 receptor agonist, Omidenepag isopropyl, combined with existing antiglaucoma agents in conscious ocular normotensive monkeys. J Ocul Pharmacol Ther. 2021;37:223\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2035_CR22","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s10384-021-00868-y","volume":"65","author":"M Aihara","year":"2021","unstructured":"Aihara M, Lu F, Kawata H, Iwata A, Odani-Kawabata N. Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study. Jpn J Ophthalmol. 2021;65:810\u20139.","journal-title":"Jpn J Ophthalmol"},{"key":"2035_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/IJG.0b013e3181fc8129","volume":"21","author":"M Aihara","year":"2012","unstructured":"Aihara M, Otani S, Kozaki J, Unoki K, Takeuchi M, Minami K, Miyata K. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost. J Glaucoma. 2012;21:60\u20134.","journal-title":"J Glaucoma"},{"key":"2035_CR24","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10384-021-00844-6","volume":"65","author":"M Aihara","year":"2021","unstructured":"Aihara M. Prostanoid receptor agonists for glaucoma treatment. Jpn J Ophthalmol. 2021;65:581\u201390.","journal-title":"Jpn J Ophthalmol"},{"key":"2035_CR25","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3109\/02713683.2011.593725","volume":"36","author":"RA Schachar","year":"2011","unstructured":"Schachar RA, Raber S, Courtney R, Zhang M. A phase 2, randomized, dose\u2013response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011;36:809\u201317.","journal-title":"Curr Eye Res"},{"issue":"11","key":"2035_CR26","doi-asserted-by":"publisher","first-page":"e040301","DOI":"10.1136\/bmjopen-2020-040301","volume":"29","author":"S Nakakura","year":"2021","unstructured":"Nakakura S, Kanamori A, Fukuma Y, Wakabayashi S, Nagata Y, Adachi M. Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study. BMJ Open. 2021;29(11):e040301.","journal-title":"BMJ Open"},{"key":"2035_CR27","first-page":"261","volume":"26","author":"A Arias","year":"2010","unstructured":"Arias A, Schargel K, Ussa F, Canut MI, Robles AY, S\u00e1nchez BM. Patient persistence with first-line antiglaucomatous monotherapy. Clin Ophthalmol. 2010;26:261\u2013728.","journal-title":"Clin Ophthalmol"},{"key":"2035_CR28","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s12325-017-0549-0","volume":"34","author":"Y Kuwayama","year":"2017","unstructured":"Kuwayama Y, Hashimoto M, Kakegawa R, Nomura A, Shimada F. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: effectiveness and treatment persistence. Adv Ther. 2017;34:1411\u201325.","journal-title":"Adv Ther"},{"key":"2035_CR29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1089\/jop.2020.0003","volume":"36","author":"Y Esaki","year":"2020","unstructured":"Esaki Y, Katsuta O, Kamio H, et al. The antiglaucoma agent and EP2 receptor agonist Omidenepag does not affect eyelash growth in mice. J Ocul Pharmacol Ther. 2020;36:529\u201333.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2035_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1089\/jop.2019.0079","volume":"36","author":"Y Yamamoto","year":"2020","unstructured":"Yamamoto Y, Taniguchi T, Inazumi T, et al. Effects of the selective EP2 receptor agonist Omidenepag on adipocyte differentiation in 3T3-L1 cells. J Ocul Pharmacol Ther. 2020;36:162\u20139.","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-02035-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-02035-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-02035-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T09:24:29Z","timestamp":1647077069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-02035-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["2035"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-02035-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]},"assertion":[{"value":"7 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}